Core Insights - The "Intelligent China, Set Sail for the Future" forum hosted by GF Securities focused on key sectors such as AI, robotics, new energy, innovative pharmaceuticals, and new consumption, attracting around 80 well-known listed companies and numerous top institutional investors [1][3] - The event featured over a thousand attendees, including leaders from 30 industry-leading enterprises, creating a platform for in-depth discussions on industry trends and investment opportunities [1][3] Group 1: Key Presentations - Zheng Hongmeng, Chairman of Industrial Fulian, discussed the rapid growth of the AI server market and the role of generative AI in driving data center infrastructure [5] - Zhou Qunfei, Chairman of Lens Technology, highlighted the challenges and opportunities brought by AI hardware transformation, aiming to become a leader in AI edge manufacturing [5][6] - Wang Dongning, President of Qinhuai Data, emphasized the integration of AI and energy, focusing on building a new generation of AI intelligent data centers powered by green energy [5][6] Group 2: Company Strategies - Wen Shuhao, Co-founder and Chairman of Jingtai Holdings, stressed the application of AI and robotics in accelerating drug and material discovery [6] - Jin Lei, General Manager of Changchun High-tech, outlined the company's commitment to innovation in pharmaceuticals and the expansion of its technology platforms [6][7] - GF Securities aims to enhance its research capabilities in AI, new energy, and innovative pharmaceuticals, promoting Chinese listed companies to overseas investors and strengthening its global market influence [7]

Core Insights - The "Intelligent China: Setting Sail for the Future" forum hosted by GF Securities focused on key sectors such as AI, robotics, new energy, innovative pharmaceuticals, and new consumption, attracting around 80 renowned listed companies and numerous global institutional investors [1][3] - Key speakers included leaders from major companies who shared insights on industry trends and the latest developments in their businesses, emphasizing the value of investing in Chinese assets [1][2] Group 1: AI and Technology - Industrial Fulian's chairman highlighted the rapid growth of the AI server market and the role of generative AI in driving data center infrastructure, focusing on the company's core advantages in AI server system assembly [1][2] - Blue Glass Technology's chairman discussed the challenges and opportunities brought by AI hardware transformation, aiming to become a leader in the trillion-yuan AI hardware market by upgrading from component supplier to solution provider [2] - Qinhuai Data's president emphasized the need for deeper integration of energy and computing, aiming to create a new generation of AI intelligent computing data centers powered by green energy [2] Group 2: Pharmaceuticals and Innovation - The co-founder of Jingtai Holdings discussed how AI and robotics can significantly enhance the speed and efficiency of drug and material discovery, addressing traditional challenges in pharmaceutical development [2] - Changchun High-tech's general manager provided an overview of the company's innovative drug pipeline, reaffirming its commitment to innovation and efficiency in the pharmaceutical sector [2][3] Group 3: Future Directions - GF Securities plans to strengthen its research team in response to global industrial changes, focusing on AI, new energy, and innovative pharmaceuticals, while promoting Chinese listed companies to overseas investors [3]

Core Viewpoint - Changchun High-tech (000661) is focusing on enhancing its core competitiveness by concentrating on traditional strengths in endocrine metabolism and women's health, as well as innovative directions related to oncology, respiratory, and immune systems [1] Product Development - The company is steadily advancing the research and development of products with differentiation and global market potential, currently having over 40 candidate drugs in clinical stages or for which new drug clinical trial applications (IND) have been submitted [1]

Core Viewpoint - The company is focusing on the development and sales of new products with high market potential, aiming to drive new business growth and diversify its operations [1] Group 1 - The company is actively promoting the research and sales of key new products [1] - The company is working to transform and upgrade its operations through diversification [1] - Increased expenditure is noted due to the push for new product development [1] Group 2 - The pharmaceutical industry requires a market cultivation period for new product sales to gain traction [1]

Core Viewpoint - The company is facing scrutiny regarding its high R&D expenses compared to its limited output, raising questions about potential misallocation of resources and the effectiveness of its research strategy [1] Group 1: R&D Investment - The company's R&D expenses are reported to be over three times that of Sanofi, yet the results from these investments are less than one percent of Sanofi's [1] - The company is focusing on enhancing its core competitiveness by concentrating on traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to oncology, respiratory, and immunology [1] Group 2: Product Development - The company is actively advancing its product development pipeline, with over 40 candidates currently in clinical stages or having submitted Investigational New Drug (IND) applications [1]

Group 1 - The core viewpoint of the article highlights that Changchun Gaoxin, as a leading local enterprise, is actively responding to the severe influenza situation in Changchun by promoting its vaccine products [2] - The company’s subsidiary, Baike Biological, currently has a nasal spray influenza vaccine (powder form) and has recently obtained production approval for a liquid nasal spray influenza vaccine [2] - Changchun Gaoxin is committed to advancing the production and sales of these related products to support local efforts against the influenza outbreak [2]

长春高新在投资者互动平台回答称，为持续提升公司核心竞争力，公司聚焦内分泌代谢、女性健康等传 统优势领域与肿瘤、呼吸、免疫相关创新方向，并稳步推进有差异化和全球市场潜力的产品研发相关工 作，目前有逾40种处于临床阶段或已提交新药临床试验申请（IND）的候选药物。 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, specifically recommending the innovative drug and medical device industry chain [5][10]. Core Insights - The pharmaceutical sector shows a positive recovery trend in Q3 2025, with overall revenue growth of 0.6% year-on-year and a net profit increase of 0.3% year-on-year. This indicates a return to growth after previous declines [6][13]. - Specific segments such as medical devices and medical research outsourcing are experiencing significant growth, with revenue and net profit growth rates of 10.6% and 0.6% for medical devices, and 10.9% and 47.9% for medical research outsourcing, respectively [13][14]. - The report highlights a continued recommendation for specific A-share and H-share stocks, including 恒瑞医药 (Hengrui Medicine), 科伦药业 (Kelun Pharmaceutical), and others, indicating strong potential for investment [7][10]. Summary by Sections 1. Continued Recommendation for Innovative Drug and Medical Device Industry Chain - The report continues to recommend the innovative drug and medical device industry chain, maintaining "Overweight" ratings for several A-share stocks including 恒瑞医药, 科伦药业, and others, and H-share stocks like 翰森制药 and 三生制药 [7][10]. 2. Recovery Trend in Pharmaceutical Sector Q3 2025 - The pharmaceutical sector's overall revenue increased by 0.6% year-on-year in Q3 2025, with net profit rising by 0.3%. Medical devices and medical research outsourcing are leading this recovery with notable growth rates [13][14]. 3. Performance of Pharmaceutical Sector in October 2025 - In October 2025, the pharmaceutical sector underperformed compared to the broader market, with the SW pharmaceutical index declining by 1.8% while the Shanghai Composite Index rose by 1.9% [15][26]. 4. Performance of Hong Kong and US Pharmaceutical Sectors - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 11.1%, while the US pharmaceutical sector showed strength with a 3.5% increase in the S&P healthcare index [26][27]. 5. Valuation and Premium Levels - As of October 31, 2025, the pharmaceutical sector's premium level relative to all A-shares is at a normal level, with a current relative premium rate of 76.7% [25][28].

Investment Rating - The report maintains a focus on innovative pharmaceuticals and medical devices, highlighting key A-share and H-share targets for investment [6][32]. Core Insights - The pharmaceutical sector showed a good recovery in Q3 2025, with overall revenue increasing by 0.6% year-on-year and net profit attributable to shareholders rising by 0.3% year-on-year [11][32]. - Medical equipment benefited from procurement recovery, with Q3 revenue and net profit growth of 10.6% and 0.6% year-on-year, respectively [11][32]. - Medical R&D outsourcing continued to achieve high growth, with Q3 revenue and net profit growth of 10.9% and 47.9% year-on-year [11][32]. - The offline pharmacy sector improved, with Q3 revenue and net profit growth of 2.1% and 37.8% year-on-year [11][32]. Summary by Sections 1. Focus on Innovative Pharmaceuticals and Medical Devices - Key A-share targets include Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Changchun High-tech Industry, Jiangsu Nhwa Pharmaceutical, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, APT Medical, and related target Guangdong Zhongsheng Pharmaceutical [6][32]. - Key H-share targets include Hansoh Pharmaceutical Group, 3SBio, Akeso, and related target Innovent Biologics, WuXi AppTec [6][32]. 2. Q3 2025 Pharmaceutical Sector Recovery - The pharmaceutical sector's overall revenue increased by 0.6% year-on-year, with net profit attributable to shareholders up by 0.3% year-on-year [11][32]. - Specific segments such as medical devices and medical R&D outsourcing showed significant growth [11][32]. 3. October 2025 Market Performance - In October 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 1.8% while the SHCOMP rose by 1.9% [14][32]. - The relative premium of the pharmaceutical sector compared to all A-shares was at a normal level, with a current relative premium rate of 76.7% [23][32]. 4. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector underperformed, with the Hang Seng Healthcare index falling by 11.1% [24][32]. - In contrast, the U.S. S&P 500 healthcare sector rose by 3.5% [24][32].

Group 1 - Jinguang Electric won a bid for a State Grid procurement project with a total amount of 21.7976 million yuan, accounting for approximately 2.93% of the company's expected revenue for 2024 [1] - Shen Gong Co. plans to reduce its shareholding by up to 2%, equating to 340.61 million shares [2] - Guomai Culture received a government subsidy of 3.78 million yuan, representing 24.90% of its audited net profit for 2024 [2] Group 2 - Guomai Culture focuses on the development and provision of digital content operation platforms [3] - Shentong Technology's two directors plan to collectively reduce their shareholding by no more than 0.0473% [4] - Ruihua Tai intends to reduce its shareholding by up to 1%, amounting to 1.8 million shares [5] Group 3 - Guoji Automobile's wholly-owned subsidiary won a total contract project worth 809 million yuan [7] - Changcheng Technology's stock is expected to remain suspended due to potential changes in control [9] - Huabei Pharmaceutical's subsidiary received approval for a chemical raw material drug listing application [11] Group 4 - Fuyao Glass has changed its legal representative to Cao Hui [13] - Huaxi Biological plans to reduce its shareholding by up to 2%, totaling 9.6336 million shares [14] - Hopu Co. signed a procurement contract for a storage system worth 500 million yuan [15] Group 5 - ST Songfa's subsidiary plans to invest 458 million yuan in a mooring dock project [18] - Zhonghong Medical's subsidiary is expected to be selected for several centralized procurement projects [19] - Huakai Yibai's vice chairman plans to increase his shareholding by no less than 30 million yuan [20] Group 6 - Haichuang Pharmaceutical completed the first participant enrollment for a clinical trial of a drug for metabolic-associated fatty liver disease [21] - Dongfang Biological's subsidiary obtained medical device product registration certificates for multiple products [22] - Lepu Medical's rechargeable implantable deep brain stimulation system received NMPA registration approval [23] Group 7 - Changyuan Power's power generation in October decreased by 32.25% year-on-year [24] - Jinshi Yaya's diclofenac sodium sustained-release tablets passed the consistency evaluation for generic drugs [26] - Yutong Bus sold 3,040 buses in October, a decrease of 5.62% year-on-year [27] Group 8 - Far East Co. signed contracts worth 1.062 billion yuan in October [28] - Tianya Pharmaceutical's subsidiary passed the consistency evaluation for a drug [29] - Yuheng Pharmaceutical plans to resolve a debt dispute through a share transfer agreement [30] Group 9 - Hailanxin's subsidiary won a bid for a marine observation network project worth 1.097 billion yuan [31] - Huasheng Lithium plans to reduce its shareholding by up to 0.37% [33] - Maike Biological obtained product registration certificates for five new in vitro diagnostic products [34] Group 10 - Huayuan New Materials signed a strategic cooperation agreement with Taiblue New Energy [37] - Greebo's actual controller and some directors plan to collectively increase their shareholding by no less than 11.5 million yuan [39] - Yian Technology received a government subsidy of 1.1643 million yuan [41] Group 11 - Kangtai Biological's quadrivalent influenza virus vaccine has commenced Phase I clinical trials [43] - Spring Airlines received a commitment letter for a stock repurchase loan of up to 450 million yuan [45] - Foton Motor sold 8,006 new energy vehicles in October, a year-on-year increase of 98.83% [46] Group 12 - Greebo plans to transfer 100% equity of its subsidiary for 280 million yuan [48] - Siwei Liekong's director is under investigation [49] - Dingyang Technology launched a new generation of multi-channel microwave signal generator products [50] Group 13 - Jiangling Motors reported a year-on-year increase of 8.06% in vehicle sales for October [51] - Shengyi Technology plans to reduce its shareholding by up to 1.03% [52] - Dongshan Precision completed the acquisition of 100% equity of France's GMD Group for approximately 814 million yuan [53] Group 14 - Tianyang Technology plans to acquire 7.5% of Baoland's shares for 155 million yuan [54] - Alter plans to establish a joint venture company with a total investment of 672 million yuan [54] - Changchun High-tech's clinical trial application for a drug was approved [55] Group 15 - Beibu Gulf Port's cargo throughput in October increased by 22.73% year-on-year [56] - ST Zhangjiajie was ruled by the court to undergo reorganization [57] - Teda Co.'s subsidiary was selected as a supplier for an energy project in Indonesia [58]